

From: Cagungun, Nannette
Sent: Monday, June 27, 2016 1:03 PM
To: 'jcastillo@Portola.com'
Subject: Labeling Information Request

Our Reference: BL 125586/0

Dear Ms. Castillo:

We are reviewing your December 17, 2015 biologics license application (BLA) for Coagulation Factor Xa (Recombinant), Inactivated, and have the following request for information:

1. Please submit an updated PI that includes your tradename and any relevant changes to the Indications and Usage, Description, Pharmacology and Clinical Trials sections.

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by July 8, 2016 referencing the date of this request. Please include both a red-line strike out and clean copy of the revised package insert in WORD format. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

The action due date for this file is August 17, 2016.

If you have any questions, please contact me at (240) 402-8267 or LT Maruna at (240) 402-8454.

Sincerely,

Nannette Cagungun, MS, PD, RAC
Regulatory Project Manager
OBRR/CBER/FDA
10903 New Hampshire Ave
WO71-4258
Silver Spring, MD 20993-0002
Tel: (240) 402-8267
Fax: (301) 595-1128
Email: nannette.cagungun@fda.hhs.gov

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are

not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.